艾意凯咨询&研发客：2025年创新前行全球共进：中国临床试验发展的新篇章研究报告（英文版）

Over the past decade, China’s clinical development landscape has undergone a remarkable transformation. The market has expanded rapidly, fueled by favorable policy reforms and sustained R&D investment from pharmas. This evolution has laid a strong foundation for the next phase of growth, one characterized by deeper innovation, greater global integration of Chinese biopharmas/biotechs and the increasing adoption of smarter tools such as artificial intelligence (AI). As the industry continu